Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on January 26, 2016, covering events occurring on January 22, 2016. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
- Board Appointment: The Board of Directors appointed Theodore R. Schroeder as a Class III director, effective January 22, 2016. His initial term expires at the 2016 annual meeting of shareholders.
- Compensation Grant: Mr. Schroeder was granted an option to purchase 15,000 shares of common stock. The option vests over a four-year period starting January 22, 2016, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments.
- Indemnification: Mr. Schroeder entered into a standard indemnification agreement with the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It explicitly states there are no related party transactions involving Mr. Schroeder reportable under Item 404(a) of Regulation S-K and no undisclosed arrangements regarding his selection.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 15,000 share option grant on potential dilution.
- Review the Company's Form S-1/A (File No. 333-208641) to confirm the specific annual cash compensation amount for non-employee directors.
- Confirm the vesting schedule details and any acceleration clauses in the stock option agreement.
- Check the press release dated January 25, 2016 (Exhibit 99.1) for additional context on Mr. Schroeder's qualifications.